Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†

(2014) I. A. McNeish et al.   ANNALS OF ONCOLOGY

A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621

(2014) Julian R. Molina et al.   LUNG CANCER

Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer

(2014) B. Moy et al.   ONCOLOGIST

The Role of Src in Colon Cancer and Its Therapeutic Implications

(2013) Jiezhong Chen et al.   Clinical Colorectal Cancer

A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non–Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium

(2013) Scott A. Laurie et al.   Clinical Lung Cancer

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

(2013) John H. Strickler et al.   INVESTIGATIONAL NEW DRUGS

Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation

(2012) Guofeng Xie et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma

(2012) Tara C. Gangadhar et al.   INVESTIGATIONAL NEW DRUGS

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

(2011) M. Campone et al.   ANNALS OF ONCOLOGY

Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer

(2011) Ayca Gucalp et al.   Clinical Breast Cancer

EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies

(2011) V. Poindessous et al.   CLINICAL CANCER RESEARCH

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium

(2011) Helen J. Mackay et al.   INVESTIGATIONAL NEW DRUGS

Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium

(2011) Manish R. Sharma et al.   INVESTIGATIONAL NEW DRUGS

Current Status of Src Inhibitors in Solid Tumor Malignancies

(2011) L. N. Puls et al.   ONCOLOGIST

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

(2010) J. Baselga et al.   CLINICAL CANCER RESEARCH

A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

(2010) Daniel J. Renouf et al.   INVESTIGATIONAL NEW DRUGS

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

(2010) E F Dunn et al.   ONCOGENE

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study

(2009) Primo N. Lara et al.   ANTI-CANCER DRUGS

Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress

(2009) S. Kopetz et al.   CANCER RESEARCH

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

(2009) Tim P. Green et al.   Molecular Oncology

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma

(2008) P. Koppikar et al.   CLINICAL CANCER RESEARCH

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

(2008) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY